JOSEPH JANKOVIC to Animals
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Animals.
Connection Strength
0.978
-
Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol. 2020 06; 16(6):303-318.
Score: 0.039
-
[Essential tremor: genetic update]. Expert Rev Mol Med. 2019 12 10; 21:e8.
Score: 0.038
-
Immunogenicity Associated with Botulinum Toxin Treatment. Toxins (Basel). 2019 08 26; 11(9).
Score: 0.037
-
Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019 08; 65:39-48.
Score: 0.036
-
Immunologic treatment of Parkinson's disease. Immunotherapy. 2018 02; 10(2):81-84.
Score: 0.033
-
The genetics of Parkinson disease. Ageing Res Rev. 2018 Mar; 42:72-85.
Score: 0.033
-
Botulinum toxin: State of the art. Mov Disord. 2017 Aug; 32(8):1131-1138.
Score: 0.032
-
Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec; 17(18):2461-2470.
Score: 0.031
-
Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol. 2016 Mar; 12(3):175-85.
Score: 0.029
-
Botulinum Toxin for the Treatment of Tremor and Tics. Semin Neurol. 2016 Feb; 36(1):54-63.
Score: 0.029
-
The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2016 Jan; 22 Suppl 1:S162-5.
Score: 0.028
-
The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015 Mar; 30(3):313-27.
Score: 0.027
-
The future of research in Parkinson disease. JAMA Neurol. 2014 Nov; 71(11):1351-2.
Score: 0.026
-
Genetic convergence of Parkinson's disease and lysosomal storage disorders. Mol Neurobiol. 2015; 51(3):1554-68.
Score: 0.026
-
Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics. 2014 Jan; 11(1):92-110.
Score: 0.025
-
Editorial: Neurotherapeutics of movement disorders. Neurotherapeutics. 2014 Jan; 11(1):3-5.
Score: 0.025
-
Restless legs syndrome and cerebrovascular disease - authors' reply. Lancet Neurol. 2013 Aug; 12(8):734-5.
Score: 0.024
-
Movement disorders in cerebrovascular disease. Lancet Neurol. 2013 Jun; 12(6):597-608.
Score: 0.024
-
The VPS35 gene and Parkinson's disease. Mov Disord. 2013 May; 28(5):569-75.
Score: 0.024
-
Preclinical biomarkers of Parkinson disease. Arch Neurol. 2011 Jan; 68(1):22-30.
Score: 0.020
-
Alcohol in essential tremor and other movement disorders. Mov Disord. 2010 Oct 30; 25(14):2274-84.
Score: 0.020
-
Advances in the pharmacological management of Huntington's disease. Drugs. 2010 Mar 26; 70(5):561-71.
Score: 0.019
-
Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009; 11(5):293-307.
Score: 0.018
-
Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist. 2009 Feb; 15(1):28-35.
Score: 0.017
-
Genetics of essential tremor. Brain. 2007 Jun; 130(Pt 6):1456-64.
Score: 0.016
-
The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005 Sep-Oct; 77(1-2):128-38.
Score: 0.014
-
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol. 2005 Jul; 4(7):423-31.
Score: 0.014
-
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges. Pharmacol Res. 2025 Jun; 216:107770.
Score: 0.014
-
Genetic mouse models of essential tremor: are they essential? J Clin Invest. 2005 Mar; 115(3):584-6.
Score: 0.014
-
Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol. 2004 Aug; 17(4):437-42.
Score: 0.013
-
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol. 2003 Jan-Feb; 26(1):18-23.
Score: 0.012
-
De novo variants in FRMD5 are associated with developmental delay, intellectual disability, ataxia, and abnormalities of eye movement. Am J Hum Genet. 2022 10 06; 109(10):1932-1943.
Score: 0.011
-
Levodopa strengths and weaknesses. Neurology. 2002 Feb 26; 58(4 Suppl 1):S19-32.
Score: 0.011
-
Essential tremor. Nat Rev Dis Primers. 2021 11 11; 7(1):83.
Score: 0.011
-
Parkinson's disease. A half century of progress. Neurology. 2001 Nov; 57(10 Suppl 3):S1-3.
Score: 0.011
-
Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001 Sep-Oct; 24(5):247-53.
Score: 0.011
-
Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001; 18(6):389-96.
Score: 0.010
-
Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998 Jun; 50(6):1624-9.
Score: 0.008
-
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
Score: 0.008
-
Myorhythmia: phenomenology, etiology, and treatment. Mov Disord. 2015 Feb; 30(2):171-9.
Score: 0.007
-
Sensory aspects of movement disorders. Lancet Neurol. 2014 Jan; 13(1):100-12.
Score: 0.006
-
Radiofrequency lesioning through deep brain stimulation electrodes: a pilot study of lesion geometry and temperature characteristics. J Clin Neurosci. 2013 Dec; 20(12):1709-12.
Score: 0.006
-
Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013 Nov; 28(13):1775-83.
Score: 0.006
-
Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets. 2012 Sep; 11(6):768-73.
Score: 0.006
-
Iron dysregulation in movement disorders. Neurobiol Dis. 2012 Apr; 46(1):1-18.
Score: 0.005
-
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012 Jan 26; 1(1):2-12.
Score: 0.005
-
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
Score: 0.005
-
Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals. 2011; 19(3):163-74.
Score: 0.005
-
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J Neurochem. 2010 Oct; 115(1):188-99.
Score: 0.005
-
Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis. 2010 Feb; 37(2):307-13.
Score: 0.005
-
Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008 Oct 14; 71(16):1275-82.
Score: 0.004
-
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
Score: 0.004
-
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
Score: 0.004
-
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis. 2008 Oct; 32(1):16-25.
Score: 0.004
-
Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 2008 Jul 30; 1222:222-9.
Score: 0.004
-
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 2008 Jun; 105(5):1970-8.
Score: 0.004
-
Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 2007 Dec; 21(14):3835-44.
Score: 0.004
-
A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007 Jan-Feb; 20(1):15-21.
Score: 0.004
-
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb; 44(5):1029-41.
Score: 0.004
-
Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice. FASEB J. 2005 Sep; 19(11):1441-50.
Score: 0.004
-
Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol. 2005 Jan; 191(1):154-62.
Score: 0.003
-
Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004 Mar-Apr; 27(2):63-73.
Score: 0.003
-
Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem. 2003 Sep; 86(6):1338-45.
Score: 0.003
-
A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics. 2003 Aug; 4(4):199-205.
Score: 0.003
-
Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. Life Sci. 2003 Jan 17; 72(9):1073-83.
Score: 0.003
-
Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging. 2003; 20(10):711-21.
Score: 0.003
-
Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov; 31(3-4):247-62.
Score: 0.003
-
Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000 Mar 10; 281(2-3):167-70.
Score: 0.002
-
Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm (Vienna). 2000; 107(10):1165-73.
Score: 0.002
-
Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 1999 Nov; 73(5):2218-21.
Score: 0.002
-
Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol. 1999 Oct; 159(2):451-8.
Score: 0.002
-
Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May; 66(5):612-6.
Score: 0.002
-
Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999; 64(15):1275-85.
Score: 0.002
-
Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998 Jan; 13(1):150-4.
Score: 0.002
-
(-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett. 1997 Mar 21; 224(3):197-200.
Score: 0.002